Related Experiment Video
Updated: May 12, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Inflammation in atherothrombotic disease
1Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger East, Montreal, QC H1T IC8, Canada. Philippe.lallier@sympatico.ca
Insights
Vascular inflammation is central to atherosclerosis, a systemic disease. Targeting inflammation offers a promising new therapeutic strategy for cardiovascular risk reduction.
Area of Science:
- Cardiovascular Science
- Immunology
- Pathophysiology
Background:
- Atherosclerosis is a systemic vascular disease where inflammation is a critical factor.
- Inflammation is implicated throughout all disease stages, from asymptomatic development to clinical events.
Purpose of the Study:
- To highlight the pivotal role of vascular inflammation in atherosclerosis.
- To underscore the predictive value of inflammatory mediators for cardiovascular risk.
- To discuss emerging anti-inflammatory therapies for atherosclerosis treatment.
Main Methods:
- Review of epidemiologic evidence linking inflammatory mediators to cardiovascular risk.
- Analysis of the role of inflammation in atherosclerosis progression.
- Examination of current research on novel anti-inflammatory drugs.
Main Results:
- C-reactive protein, an inflammatory mediator, independently predicts cardiovascular risk.
- Inflammation is a key driver of atherosclerosis from initiation to manifestation.
- Investigational drugs targeting inflammation show potential for modifying disease course.
Conclusions:
- Vascular inflammation is a fundamental aspect of atherosclerosis.
- Inflammatory markers are significant predictors of cardiovascular events.
- Targeting inflammation represents a promising future therapeutic avenue for managing atherosclerosis.
Abstract:
Atherosclerosis is a systemic disease in which vascular inflammation plays a key role. Indeed, inflammation is closely linked to atherosclerotic disease at all stages, from silent progression to clinical manifestations. There is now strong epidemiologic evidence that mediators of inflammation, like C-reactive protein, predict cardiovascular risk independently of "classical" risk factors. Consequently, new disease-modifying drugs targeting inflammation are under investigation and may change the approach to treatment of atherosclerosis in the near future.
More Related Videos
Related Concept Videos
Inflammation
Atherosclerosis I: Introduction
Peripheral Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Acute Inflammation I: Inflammatory Response
Chronic Inflammation: Introduction
